Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will India’s Sun Rise On Stada? Bankers, Analysts Divided On Risks, Benefits

This article was originally published in PharmAsia News

Executive Summary

Stada’s financial woes may not be primary factors for Sun to bid but analysts reason there may be value accretive points.

You may also be interested in...



Sun Finally Gains Control Of Taro As Founders Relent; Charts Out Aggressive Investment And Growth Plans

HYDERABAD - Bound by Israel's Supreme Court verdict earlier this month, drug firm Taro's founders - the Levitt and Moros families - have finally conceded management control of the 60-year old company that specializes in dermatology products to Sun Pharma - India's largest company by market capitalization

Germany's Discount Contracts Are Changing The Pharma Market Landscape

Regional firm wins an important tender, but at a discount that is so steep it attacks the process as creating "only losers."

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Topics

Related Companies

UsernamePublicRestriction

Register

SC082106

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel